News | January 06, 2022
Aurobindo Pharma rolls out Molnaflu in India
The brand is now available pan-India through their distribution partner
The brand is now available pan-India through their distribution partner
It is the generic version of molnupiravir
It has also been granted permission to conduct trials for booster dose
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
A toll-free helpline to be set up to help doctors and patients
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
Subscribe To Our Newsletter & Stay Updated
